Therapeutic Potential of Drug Delivery by Means of Lipid Nanoparticles: Reality or Illusion?

Uner M., Damgali S., Ozdemir S., Celik B.

CURRENT PHARMACEUTICAL DESIGN, vol.23, no.43, pp.6573-6591, 2017 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 23 Issue: 43
  • Publication Date: 2017
  • Doi Number: 10.2174/1381612823666171122110638
  • Journal Name: CURRENT PHARMACEUTICAL DESIGN
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.6573-6591
  • Keywords: Solid lipid nanoparticles, nanostructured lipid carriers, controlled drug delivery, colloidal drug carriers, stealth nanoparticles, targeting, IMPROVED ORAL BIOAVAILABILITY, LONG-TERM STABILITY, IN-VIVO EVALUATION, CARRIERS NLC, DERMAL DELIVERY, BRAIN DELIVERY, GENE-THERAPY, INTRANASAL DELIVERY, TOPICAL DELIVERY, OCULAR DELIVERY
  • Istanbul University Affiliated: Yes

Abstract

Background: Solid lipid nanoparticles (SLN) are colloidal drug carrier systems that contribute several properties required from a sophisticated drug delivery system for increasing drug bioavailability and providing effective therapy. Many advantages of SLN have been reported over traditional dosage forms and their colloidal counterparts since the early 1990s. They were optimized for oral drug delivery for the first time. The first SLN formulations were produced by reducing particle size of solid lipid microparticles by spray congealing technique in the late 1980s. Then, studies have been continued investigating for their different administration routes else including parenteral, transdermal, ocular, nasal, respiratory etc.